Pfizer Collaborates with Sangamo on Gene Therapy Programmes for Haemophilia A
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 5 (Table of Contents)
Published: 29 May-2017
DOI: 10.3833/pdr.v2017.i5.2251 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer has expanded its gene therapy portfolio in a deal valued at US$545 M with Sangamo Therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS